Table 3

Response rate

AllTN (n=15)HR+ (n=14)
Objective response rate4 (14%)2 (13%)2 (14%)
Partial response (PR)4 (14%)2 (13%)2 (14%)
Stable disease (SD)12 (41%)5 (33%)7 (50%)
Progressive disease13 (43%)8 (50%)5 (36%)
Not evaluable1 (3%)1 (6%)0
Clinical benefit rate
(=PR+SD >6 months)
8 (28%)4 (27%)4 (28%)
  • HR+, hormone receptor-positive endocrine-refractory ; TN, triple negative.